Last reviewed · How we verify
Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab
Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab is a Small molecule drug developed by Gustave Roussy, Cancer Campus, Grand Paris. It is currently in Phase 2 development.
At a glance
| Generic name | Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab |
|---|---|
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (PHASE2, PHASE3)
- Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (PHASE2)
- Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (PHASE2)
- Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (PHASE2)
- Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas (PHASE1, PHASE2)
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab CI brief — competitive landscape report
- Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab updates RSS · CI watch RSS
- Gustave Roussy, Cancer Campus, Grand Paris portfolio CI
Frequently asked questions about Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab
What is Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab?
Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab is a Small molecule drug developed by Gustave Roussy, Cancer Campus, Grand Paris.
Who makes Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab?
Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab is developed by Gustave Roussy, Cancer Campus, Grand Paris (see full Gustave Roussy, Cancer Campus, Grand Paris pipeline at /company/gustave-roussy-cancer-campus-grand-paris).
What development phase is Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab in?
Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab is in Phase 2.